Condition or Therapy:

Solid tumors 

Category:

Cancer and Blood Disorders

What is the goal of this study?

This is a multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients with NTRK fusion cancers treated with a prior TRK inhibitor.

Who can join the study?

This study is for patients with relapsed or refractory solid tumors that are 1 month old or older.

What will happen if my child takes part in this study?

You can read the complete study protocol on clinicaltrials.gov.

Who can I contact for more information?

For more information, call the study team at 206-884-1149 or send us an email.


Study Location(s):

Seattle Children's Hospital main campus 

Principal Investigator:

Dr. Katie Albert